Aryx Therapeutics I
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the tre… Read more
Aryx Therapeutics I (ARYX) - Total Assets
Latest total assets as of September 2010: $5.97 Million USD
Based on the latest financial reports, Aryx Therapeutics I (ARYX) holds total assets worth $5.97 Million USD as of September 2010.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aryx Therapeutics I - Total Assets Trend (2003–2009)
This chart illustrates how Aryx Therapeutics I’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aryx Therapeutics I - Asset Composition Analysis
Current Asset Composition (December 2009)
Aryx Therapeutics I's total assets of $5.97 Million consist of 71.0% current assets and 29.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $2.26 Million | 18.2% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2009)
This chart illustrates how Aryx Therapeutics I's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aryx Therapeutics I's current assets represent 71.0% of total assets in 2009, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 59.7% of total assets in 2009, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is property, plant & equipment at 18.2% of total assets.
Aryx Therapeutics I Competitors by Total Assets
Key competitors of Aryx Therapeutics I based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Aryx Therapeutics I - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Aryx Therapeutics I generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aryx Therapeutics I is currently not profitable relative to its asset base.
Aryx Therapeutics I - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.47 | 1.52 | 3.58 |
| Quick Ratio | 0.47 | 1.52 | 3.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.11 Million | $ 5.15 Million | $ 19.97 Million |
Aryx Therapeutics I - Advanced Valuation Insights
This section examines the relationship between Aryx Therapeutics I's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 37.83 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -75.7% |
| Total Assets | $12.41 Million |
| Market Capitalization | $4.75 USD |
Valuation Analysis
Below Book Valuation: The market values Aryx Therapeutics I's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aryx Therapeutics I's assets decreased by 75.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aryx Therapeutics I (2003–2009)
The table below shows the annual total assets of Aryx Therapeutics I from 2003 to 2009.
| Year | Total Assets | Change |
|---|---|---|
| 2009-12-31 | $12.41 Million | -75.74% |
| 2008-12-31 | $51.15 Million | -26.54% |
| 2007-12-31 | $69.62 Million | +22.66% |
| 2006-12-31 | $56.76 Million | +70.40% |
| 2005-12-31 | $33.31 Million | +276.53% |
| 2003-12-31 | $8.85 Million | -- |